Diamond Pharma Services' acquisition strengthens pharmacovigilance division

The acquisition will enhance senior-level expertise, which will support clients from Diamond’s regulatory affairs business in specialist areas such as gene and cell therapies.

The acquisition will expand Diamond’s presence in Europe and enhance the senior-level expertise within its pharmacovigilance team.

PharmaCentral offers a wide range of pharmacovigilance consultancy services, based on a wealth of experience in pharmacovigilance and medical affairs in both pharma and CRO environments. The acquisition of PharmaCentral forms part of Diamond’s growth strategy for its pharmacovigilance division, which has achieved a Compound Annual Growth Rate (CAGR) in revenues of 27% over the last 3 years. This rapid expansion of Diamond’s pharmacovigilance senior-level team is required to support clients from Diamond’s regulatory affairs business in specialist areas such as gene and cell therapies.

Diamond Pharma Services provides regulatory affairs, pharmacovigilance and compliance & quality services to support pharmaceutical and biotechnology companies in obtaining and maintaining medicinal product licences throughout all stages of a product’s lifecycle. Diamond will continue to expand its presence in Dublin through 2020, with recruitment across all three of its divisions.

David Boyd, Managing Director, Diamond PV Services, said: “We have seen strong organic growth over the last 3 years, which has driven us to evaluate our resources, including our in-house expertise, processes and systems. This acquisition will help support the next phase of growth, representing a step change in our senior team.”